Validation of Sensitivity and Specificity of a Multi-Omic Precision Diagnostic for Acute Stroke Evaluation
Valtari Bio’s current VALISS clinical trial is validating the clinical utility of our multi-omic biomarker profile to facilitate the early identification of suspected stroke patients in the emergency room. The trial will validate our final multi-omic biomarker profile in order to prototype our diagnostic assay on a handheld device.
Up to two hundred and fifty patients aged 18 years or older who present to the hospital with suspected stroke symptoms will be recruited within 12 hours of symptom onset. Final diagnoses may include: ischemic stroke (IS), TIA, aneurysmal subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH) with or without intraventricular hemorrhage (IVH) (or primary IVH), and stroke mimic (all other patients presenting with acute onset stroke-like symptoms who do not have ischemic or hemorrhagic stroke. Subjects will be recruited at the University of Cincinnati Medical Center (UCMC) and/or participating regional hospitals served by the UC Stroke Team.
To learn more, click VALISS Clinical Trial. ClinicalTrials.gov Identifier: NCT02753257